[go: up one dir, main page]

WO1994002510A3 - Analogues de parathormone - Google Patents

Analogues de parathormone Download PDF

Info

Publication number
WO1994002510A3
WO1994002510A3 PCT/EP1993/001749 EP9301749W WO9402510A3 WO 1994002510 A3 WO1994002510 A3 WO 1994002510A3 EP 9301749 W EP9301749 W EP 9301749W WO 9402510 A3 WO9402510 A3 WO 9402510A3
Authority
WO
WIPO (PCT)
Prior art keywords
pth
amino acid
8alkynyl
8alkenyl
8alkyl
Prior art date
Application number
PCT/EP1993/001749
Other languages
English (en)
Other versions
WO1994002510A2 (fr
Inventor
Wilfried Bauer
Robin Breckenridge
Francois Cardinaux
Frank Gombert
Hermann Gram
Paul Ramage
Helmut Schneider
Rudolf Waelchli
Rainer Albert
Ian Lewis
Original Assignee
Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H.
Sandoz-Patent-Gmbh
Sandoz Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215009A external-priority patent/GB9215009D0/en
Priority claimed from GB929226415A external-priority patent/GB9226415D0/en
Priority claimed from GB929226861A external-priority patent/GB9226861D0/en
Priority claimed from GB929226859A external-priority patent/GB9226859D0/en
Priority claimed from GB939301692A external-priority patent/GB9301692D0/en
Priority claimed from GB939301691A external-priority patent/GB9301691D0/en
Priority claimed from GB939307673A external-priority patent/GB9307673D0/en
Priority claimed from GB939308033A external-priority patent/GB9308033D0/en
Priority to DE4393381A priority Critical patent/DE4393381B4/de
Application filed by Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H., Sandoz-Patent-Gmbh, Sandoz Ltd. filed Critical Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H.
Priority to DK93915814T priority patent/DK0672057T3/da
Priority to ES93915814T priority patent/ES2150948T3/es
Priority to DE4393381T priority patent/DE4393381T1/de
Priority to EP93915814A priority patent/EP0672057B1/fr
Priority to RU94046405A priority patent/RU2130945C1/ru
Priority to AT0903993A priority patent/AT408100B/de
Priority to SK43-95A priority patent/SK283485B6/sk
Priority to PL93306556A priority patent/PL179733B1/pl
Publication of WO1994002510A2 publication Critical patent/WO1994002510A2/fr
Publication of WO1994002510A3 publication Critical patent/WO1994002510A3/fr
Priority to NO19950123A priority patent/NO319448B1/no
Priority to FI950171A priority patent/FI113872B/fi
Priority to GR20000402777T priority patent/GR3035089T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des composés de parathormone et ayant l'activité de cette hormone, avec au moins une modification. Cette modification peut consister soit 1) en au moins un radical choisi parmi les acides α-aminés L ou D, un groupe alcoxycarbonyle C2-6 et les groupes (le cas échéant substitués) alkyle C1-8, alcényle C2-8, alcynyle C2-8, aralkyle, aralcényle ou cycloalkyl C3-6- alkyle C1-4 et fixé au groupe amino terminal de la parathormone, et/ou au moins un radical choisi parmi les groupes alcoxycarbonyle C2-6 et les groupes (le cas échéant substitués) alkyle C1-8, alcényle C2-8, alcynyle C2-8, aralkyle, aralcényle ou cycloalkyl C3-6-alkyle C1-4 et fixé à un ou plusieurs groupes amino à chaînes latérales du composé de parathormone, soit 2) en au moins une unité d'acide α-aminé dans les positions 1 à 38 de la séquence naturelle de la parathormone remplacée par une unité d'acide α-aminé naturel ou non, le cas échéant sous une forme protégée, les unités d'acide α-aminé en position 1 et 2 à la terminaison amino de la séquence de la parathormone pouvant être remplacées par un pseudo-peptide, soit en une combinaison de telles modifications. Ce polypeptide sous forme libre ou d'un sel a une activité pharmacologique utile dans la prévention ou le traitement d'états pathologiques osseux provoqués par une décalcification osseuse ou une résorption osseuse, ou encore dans le traitement d'états nécessitant une amélioration de la fixation du calcium dans les os.
PCT/EP1993/001749 1992-07-15 1993-07-06 Analogues de parathormone WO1994002510A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DK93915814T DK0672057T3 (da) 1992-07-15 1993-07-06 Analoger af PTH
ES93915814T ES2150948T3 (es) 1992-07-15 1993-07-06 Analogos de pth.
DE4393381T DE4393381T1 (de) 1992-07-15 1993-07-06 Peptide
EP93915814A EP0672057B1 (fr) 1992-07-15 1993-07-06 Analogues de parathormone
DE4393381A DE4393381B4 (de) 1992-07-15 1993-07-06 PTH-Verbindungen mit PTH-ähnlicher Aktivität, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Zusammensetzungen und deren Verwendungen
PL93306556A PL179733B1 (pl) 1993-07-06 1993-07-06 Z wiazek majacy aktywnosc PTH-podobna, sposób wytwarzania zwiazku majacego aktywnosc PTH-podobna, sekwencja nukleotydowa kodujaca bialko fuzyjne, bakteryjny wektor ekspresyjny, bakteryjne komórki gospodarzastransformowane sekwencja DNA kodujaca bialko fuzyjne, bialko fuzyjne oraz kompozycja farmaceutyczna zawierajaca zwiazek majacy aktywnosc PTH-podobna PL PL PL PL PL
SK43-95A SK283485B6 (sk) 1992-07-15 1993-07-06 Deriváty parathormónu, spôsob ich prípravy a farmaceutické kompozície, ktoré ich obsahujú
AT0903993A AT408100B (de) 1992-07-15 1993-07-06 Pth-analoga
RU94046405A RU2130945C1 (ru) 1993-04-19 1993-07-06 Птг-соединения и способ их получения, содержащая их фармацевтическая композиция, фрагмент днк и слитый белок
NO19950123A NO319448B1 (no) 1992-07-15 1995-01-12 PTH-analoger, fremgangsmater for deres fremstilling og farmasoytiske preparater inneholdende disse, samt nukleotidsekvenser, ekspresjonsvektorer og vertsceller.
FI950171A FI113872B (fi) 1992-07-15 1995-01-13 Menetelmä PTH-analogien valmistamiseksi
GR20000402777T GR3035089T3 (en) 1992-07-15 2000-12-15 Analogs of pth.

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
GB9215009.3 1992-07-15
GB929215009A GB9215009D0 (en) 1992-07-15 1992-07-15 Organic compounds
GB929226415A GB9226415D0 (en) 1992-12-18 1992-12-18 Organic compounds
GB9226415.9 1992-12-18
GB929226859A GB9226859D0 (en) 1992-12-23 1992-12-23 Organic compounds
GB9226859.8 1992-12-23
GB9226861.4 1992-12-23
GB929226861A GB9226861D0 (en) 1992-12-23 1992-12-23 Organic compounds
GB9301692.1 1993-01-28
GB939301691A GB9301691D0 (en) 1993-01-28 1993-01-28 Organic compounds
GB9301691.3 1993-01-28
GB939301692A GB9301692D0 (en) 1993-01-28 1993-01-28 Organic compounds
GB939307673A GB9307673D0 (en) 1993-04-14 1993-04-14 Organic compounds
GB9307673.5 1993-04-14
GB9308033.1 1993-04-19
GB939308033A GB9308033D0 (en) 1993-04-19 1993-04-19 Organic compounds

Publications (2)

Publication Number Publication Date
WO1994002510A2 WO1994002510A2 (fr) 1994-02-03
WO1994002510A3 true WO1994002510A3 (fr) 1994-05-26

Family

ID=27571302

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/001749 WO1994002510A2 (fr) 1992-07-15 1993-07-06 Analogues de parathormone

Country Status (25)

Country Link
US (2) US20050009147A1 (fr)
EP (1) EP0672057B1 (fr)
JP (1) JP3164463B2 (fr)
KR (1) KR100321651B1 (fr)
CN (1) CN1051769C (fr)
AT (1) AT408100B (fr)
AU (1) AU672790B2 (fr)
CA (1) CA2100423C (fr)
CH (1) CH688195A5 (fr)
CZ (1) CZ286889B6 (fr)
DE (2) DE4393381T1 (fr)
DK (1) DK0672057T3 (fr)
ES (1) ES2150948T3 (fr)
FI (1) FI113872B (fr)
GB (1) GB2269176B (fr)
GR (1) GR3035089T3 (fr)
HK (1) HK1004896A1 (fr)
HU (2) HUT70459A (fr)
IL (1) IL106326A (fr)
NO (1) NO319448B1 (fr)
NZ (1) NZ248137A (fr)
PT (1) PT672057E (fr)
SG (1) SG63625A1 (fr)
SK (1) SK283485B6 (fr)
WO (1) WO1994002510A2 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
AU8002994A (en) * 1993-10-27 1995-05-22 Chugai Seiyaku Kabushiki Kaisha Cure accelerator in chondroplasty
CA2126299C (fr) * 1994-06-20 2000-12-12 Gordon E. Willick Analogues de l'hormone parathyroidienne utilises pour le traitement de l'osteoporose
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6110892A (en) * 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
CA2178894A1 (fr) * 1995-06-15 1996-12-16 Tsunehiko Fukuda Derives de la parathormone et leur utilisation
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US6544949B1 (en) * 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
NZ333809A (en) * 1996-08-02 2000-07-28 Ca Nat Research Council Parathyroid hormone analogues for use as medicaments in treating osteoporosis
EP1352912A1 (fr) * 1996-08-02 2003-10-15 National Research Council Of Canada Analogues de l'hormone parathyroidienne pour le traitement de l'osteoporose
EP0986395A4 (fr) 1997-05-14 2004-12-01 Aventis Pharm Prod Inc Analogues peptidiques de l'hormone parathyroide
WO1999004808A1 (fr) * 1997-07-22 1999-02-04 Chugai Seiyaku Kabushiki Kaisha Medicaments dentaires contenant de la pth
PL195703B1 (pl) * 1997-09-09 2007-10-31 Hoffmann La Roche Zastosowanie polipeptydowego analogu peptydu pokrewnego hormonowi przytarczyc
ATE392431T1 (de) 1998-05-05 2008-05-15 Sod Conseils Rech Applic Pth2 rezeptor selektive verbindungen
JP4486256B2 (ja) 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
ATE458054T1 (de) 1998-11-25 2010-03-15 Gen Hospital Corp Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
EP1147133B1 (fr) * 1998-12-31 2008-08-06 The General Hospital Corporation Peptides comprenant une fusion de deux domaines fonctionnels de la PTH par une molecule linker, et leurs dérivés
EP1612263A1 (fr) 1998-12-31 2006-01-04 The General Hospital Corporation Réceptor PTH et test de criblage l'utilisant
US7057012B1 (en) 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
DE19916419B4 (de) * 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
AU7734800A (en) 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
JP4837888B2 (ja) 2001-07-23 2011-12-14 ザ ジェネラル ホスピタル コーポレイション コンホメーションが拘束された副甲状腺ホルモン（ｐｔｈ）類似体
EP1531855A4 (fr) 2002-01-10 2009-07-22 Osteotrophin Llc Traitement des affections osseuses avec des medicaments anabolisants du squelette
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003239869A1 (en) 2002-05-23 2003-12-12 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
AU2002951372A0 (en) * 2002-09-13 2002-09-26 St Vincent's Institute Of Medical Research Parathyroid hormone-like polypeptides
WO2004093902A1 (fr) * 2003-03-19 2004-11-04 The General Hospital Corporation Hormones parathyroidiennes contraintes de maniere conformationnelle avec des stabilisateurs en helice $g(a)
US7910544B2 (en) 2003-07-17 2011-03-22 The General Hospital Corporation Conformationally constrained parthyroid hormone (PTH) analogs
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
AU2005244734A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2007028633A2 (fr) * 2005-09-08 2007-03-15 Uutech Limited Traitement de l'obesite associee aux diabetes
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
JP2009515535A (ja) * 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
MX2009003740A (es) 2006-10-13 2009-04-22 Lilly Co Eli Pth pegilado como moduladores de receptor pth y usos de los mismos.
KR101661730B1 (ko) 2007-08-01 2016-10-04 더 제너럴 하스피탈 코포레이션 Ｇ―단백질 결합 수용체를 이용한 스크리닝 방법 및 관련 조성물
US8642536B2 (en) 2008-10-17 2014-02-04 Wisconsin Alumni Research Foundation Method of making biologically active alpha-beta peptides
EP2411038B1 (fr) 2009-03-27 2016-12-28 Van Andel Research Institute Peptides de l'hormone parathyroïdienne et peptides de la protéine apparentée à l'hormone parathyroïdienne ainsi que des procédés d'utilisation
WO2011071480A1 (fr) 2009-12-07 2011-06-16 Michigan Technological University Hormone parathyroïde de l'ours noir et ses procédés d'utilisation
EP2569003B1 (fr) 2010-05-13 2017-10-25 The General Hospital Corporation Analogues de l'hormone parathyroïdienne et leurs utilisations
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
EP2680871A4 (fr) * 2011-03-01 2015-04-22 Sloan Kettering Inst Cancer Analogues de l'hormone parathyroïdienne, compositions et utilisations connexes
US20170037086A1 (en) * 2014-04-09 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
PH12021551402A1 (en) 2018-12-20 2023-05-03 Ksq Therapeutics Inc Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
CA3196564A1 (fr) 2020-10-30 2022-05-05 Hanlan Liu Formes de pyrazolopyrimidines substituees a l'etat solide et leurs utilisations
WO2023066881A1 (fr) 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition de map3k15 pour le traitement et la prévention du diabète

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2550204A1 (fr) * 1983-08-05 1985-02-08 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
EP0293158A2 (fr) * 1987-05-26 1988-11-30 Merck & Co. Inc. Antagonistes d'hormone parathyroide
EP0301485A1 (fr) * 1987-07-30 1989-02-01 Gesellschaft für Biotechnologische Forschung mbH (GBF) Vecteurs d'expression et procédé les utilisant pour la production de protéines de fusion de cro/bêta-galactosidase/PTH et de PTH
WO1990010067A1 (fr) * 1989-02-23 1990-09-07 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Sequences d'adn codant pour des variantes de pth, variantes de pth, vecteur d'expression, hote bacterien, utilisation et composition therapeutique
EP0477885A2 (fr) * 1990-09-28 1992-04-01 Takeda Chemical Industries, Ltd. Dérivées d'hormone parathyroid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US5420242A (en) * 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
US5001223A (en) * 1987-05-26 1991-03-19 Merck & Co., Inc. Parathyroid hormone antagonists with enhanced metabolic properties
US4968669A (en) * 1988-05-09 1990-11-06 Merck & Co., Inc. Parathyroid hormone antagonists
CA2040264A1 (fr) * 1990-04-12 1991-10-13 Tatsuhiko Kanmera Antagonistes de la parathormone
US5093233A (en) * 1990-04-25 1992-03-03 Merck & Co., Inc. Antagonists with position 13 modification
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
AU9103791A (en) * 1990-12-21 1992-07-22 Allelix Biopharmaceuticals Inc. Oxidation resistant variants of parathyroid hormone
ATE138102T1 (de) * 1991-02-19 1996-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von cysteinfreien peptiden
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5434246A (en) * 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5382658A (en) * 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2550204A1 (fr) * 1983-08-05 1985-02-08 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
EP0293158A2 (fr) * 1987-05-26 1988-11-30 Merck & Co. Inc. Antagonistes d'hormone parathyroide
EP0301485A1 (fr) * 1987-07-30 1989-02-01 Gesellschaft für Biotechnologische Forschung mbH (GBF) Vecteurs d'expression et procédé les utilisant pour la production de protéines de fusion de cro/bêta-galactosidase/PTH et de PTH
WO1990010067A1 (fr) * 1989-02-23 1990-09-07 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Sequences d'adn codant pour des variantes de pth, variantes de pth, vecteur d'expression, hote bacterien, utilisation et composition therapeutique
EP0477885A2 (fr) * 1990-09-28 1992-04-01 Takeda Chemical Industries, Ltd. Dérivées d'hormone parathyroid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
G.W.TREGEAR ET AL: "SYNTHETIC ANALOGS OF RESIDUES 1-34 OF HPTH;INFLUENCE OF NO.1 ON BIOLOGICAL POTENCY IN VITRO", ENDOCRINE RESEARCH COMM., vol. 2, no. 8, 1975, NEW YORK, pages 561 - 570 *
S.A.RABBANI ET AL: "RECOMBINANT HPTH SYNTHESIZED IN E.COLI", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 263, no. 3, 25 January 1988 (1988-01-25), BALTIMORE US, pages 1307 - 1313 *
S.A.RABBANI ET AL: "SYNTHESIS AND CHARACTERISATION OF EXTENDED AND DELETED RECOMBINANT ANALOGS OF PTH(1-84): CORRELATION OF PEPTIDE STRUCTURE WITH FUNCTION", BIOCHEMISTRY., vol. 29, no. 43, 30 October 1990 (1990-10-30), EASTON, PA US, pages 10080 - 10089 *

Also Published As

Publication number Publication date
AT408100B (de) 2001-08-27
JP3164463B2 (ja) 2001-05-08
US20080318838A1 (en) 2008-12-25
CH688195A5 (de) 1997-06-13
AU672790B2 (en) 1996-10-17
HUT70459A (en) 1995-10-30
GB2269176A (en) 1994-02-02
FI950171A7 (fi) 1995-03-13
KR940005670A (ko) 1994-03-22
AU4156693A (en) 1994-01-20
SK283485B6 (sk) 2003-08-05
CN1051769C (zh) 2000-04-26
EP0672057A1 (fr) 1995-09-20
NO950123D0 (no) 1995-01-12
KR100321651B1 (ko) 2002-05-13
NZ248137A (en) 1995-12-21
DK0672057T3 (da) 2000-12-27
ES2150948T3 (es) 2000-12-16
CN1099801A (zh) 1995-03-08
CZ8895A3 (en) 1995-10-18
DE4393381B4 (de) 2008-07-17
IL106326A (en) 1997-09-30
ATA903993A (de) 2001-01-15
IL106326A0 (en) 1994-04-12
NO950123L (no) 1995-03-15
EP0672057B1 (fr) 2000-09-20
GB9314384D0 (en) 1993-08-25
GB2269176B (en) 1997-01-08
CZ286889B6 (en) 2000-07-12
GR3035089T3 (en) 2001-03-30
HU9500115D0 (en) 1995-03-28
SK4395A3 (en) 1995-06-07
CA2100423C (fr) 2005-06-14
FI950171A0 (fi) 1995-01-13
JPH06184198A (ja) 1994-07-05
FI113872B (fi) 2004-06-30
US20050009147A1 (en) 2005-01-13
CA2100423A1 (fr) 1994-01-16
NO319448B1 (no) 2005-08-15
HU211856A9 (en) 1995-12-28
PT672057E (pt) 2001-02-28
DE4393381T1 (de) 1995-04-27
WO1994002510A2 (fr) 1994-02-03
SG63625A1 (en) 1999-03-30
HK1004896A1 (en) 1998-12-11

Similar Documents

Publication Publication Date Title
WO1994002510A3 (fr) Analogues de parathormone
EP0112656A3 (en) Peptide compounds
MX9703550A (es) Secretagogos de hormona del crecimiento, peptidomimeticos, de bajo peso molecular.
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
MY135057A (en) Dolastatin 15 derivatives
MY123740A (en) Il-13 receptor polypeptide
EP0669830A4 (fr) Analogues dipeptidiques substitues favorisant la liberation de l'hormone de croissance.
NZ326238A (en) Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
KR0180256B1 (en) Bpc peptides, their preparation and use
DE69723728D1 (de) Totalsynthese des amino hip analogen von didemnin a
HK73692A (en) Novel growth hormone-releasing peptides and method of treating mammals therewith
EP0312502A3 (en) Dipeptides useful as plant growth regulators
ZA878349B (en) Peptides compounds
PH30218A (en) A process for inhibiting growth or proliferation of virus
CA2075833A1 (fr) Regularisation du developpement oculaire a l'aide de neuropeptides
ES8703488A1 (es) Procedimiento para preparar peptidos
ES8300086A1 (es) Un procedimiento para preparar un peptido
PH27384A (en) Hair treatment compositions
DE3571990D1 (en) Reduced peptides, inhibitors of gastric secretion, preparation process and pharmaceutical compositions containing them
JPS6470500A (en) Somatostatin analogue compound for treatment
ES8500217A1 (es) Un procedimiento para preparar peptidos sinteticos del tipo de las calcitoninas.
MX9304251A (es) Compuestos variantes de la hormona paratiroidea, proceso para su produccion y composiciones farmaceuticas que los contienen.
PL286507A1 (en) Automatic feeder regulation system for mining combines that regulates according to the amount of stress on the mining organs
UA10342C2 (uk) Сіль 3-метиламіhосульфолаhу та п-толоксиоцтової кислоти, що має властивості регулятора росту рослиh

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT CH CZ DE FI HU NO PL RU SK

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BE DK ES FR GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AT CH CZ DE FI HU NO PL RU SK

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): BE DK ES FR GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1993915814

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1993 9039

Country of ref document: AT

Date of ref document: 19940203

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 19939039

Country of ref document: AT

WWE Wipo information: entry into national phase

Ref document number: PV1995-88

Country of ref document: CZ

Ref document number: 4395

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 950171

Country of ref document: FI

RET De translation (de og part 6b)

Ref document number: 4393381

Country of ref document: DE

Date of ref document: 19950427

WWE Wipo information: entry into national phase

Ref document number: 4393381

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 1993915814

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1995-88

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1995-88

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1993915814

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 950171

Country of ref document: FI

REG Reference to national code

Ref country code: DE

Ref legal event code: 8607